On January 23, 2026, the China National Medical Products Administration (NMPA) granted conditional approval for Libevitug injection (Huayounuo®), a treatment independently developed by Huahui Health. The drug is indicated for the treatment of chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a first-in-class antibody therapeutic for viral hepatitis and the first approved treatment for HDV in China, addressing a major clinical gap in this field.
As a trusted CDMO partner to Huahui Health, Intellective Bio provided end-to-end support, from process development through commercial manufacturing. The successful conditional approval of Libevitug represents Intellective Bio’s third client commercialization milestone, underscoring the growing maturity of our scalable commercial manufacturing capabilities and the continued validation of our platform value.
